Loading...
Loading...
XOMAP| Name | Value |
|---|---|
| Revenues | 13.1M |
| Cost of Revenue | 0.7M |
| Gross Profit | 12.5M |
| Operating Expense | 7.9M |
| Operating I/L | 4.6M |
| Other Income/Expense | 4.6M |
| Interest Income | 0.0M |
| Pretax | 9.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 9.2M |
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring potential future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets, and it helps biotech companies enhance human health by providing financial support and expertise in the development of therapeutic candidates.
